{"log_id": 2572390840839486975, "direction": 0, "words_result_num": 43, "words_result": [{"probability": {"variance": 4e-06, "average": 0.998234, "min": 0.994831}, "location": {"width": 118, "top": 192, "height": 25, "left": 219}, "words": "【临床研究】"}, {"probability": {"variance": 1e-06, "average": 0.999136, "min": 0.997152}, "location": {"width": 152, "top": 227, "height": 25, "left": 299}, "words": "院内获得性肺炎"}, {"probability": {"variance": 6e-06, "average": 0.998904, "min": 0.990409}, "location": {"width": 277, "top": 260, "height": 25, "left": 300}, "words": "复杂性皮肤和皮肤软组织感染"}, {"probability": {"variance": 1.1e-05, "average": 0.998467, "min": 0.981331}, "location": {"width": 732, "top": 293, "height": 32, "left": 299}, "words": "社区获得性肺炎(另有一个由8个月至12岁患者参加的非对照研究的证据支持"}, {"probability": {"variance": 1e-06, "average": 0.999125, "min": 0.996781}, "location": {"width": 276, "top": 329, "height": 26, "left": 300}, "words": "万古霉素耐药的屎肠球菌感染"}, {"probability": {"variance": 8e-06, "average": 0.998906, "min": 0.982005}, "location": {"width": 812, "top": 360, "height": 33, "left": 252}, "words": "一个在5至17岁儿童患者中进行的阳性对照研究证实了利奈唑胺对下列感染的安全性和"}, {"probability": {"variance": 0.000155, "average": 0.995645, "min": 0.956366}, "location": {"width": 232, "top": 393, "height": 27, "left": 207}, "words": "有效性(见【临床研究】"}, {"probability": {"variance": 3e-06, "average": 0.998619, "min": 0.991395}, "location": {"width": 763, "top": 427, "height": 31, "left": 299}, "words": "由对甲氧西林敏感的金黄色葡萄球菌和化脓性链球菌引起的非复杂性皮肤和皮肤软"}, {"probability": {"variance": 6e-06, "average": 0.998521, "min": 0.994328}, "location": {"width": 89, "top": 460, "height": 25, "left": 205}, "words": "组织感染"}, {"probability": {"variance": 1.3e-05, "average": 0.99835, "min": 0.98127}, "location": {"width": 816, "top": 491, "height": 36, "left": 247}, "words": "在经脑室腹膜分流术的儿童患者中得到的药代动力学资料显示,给予单剂或多剂利奈唑"}, {"probability": {"variance": 2.8e-05, "average": 0.998221, "min": 0.968223}, "location": {"width": 847, "top": 526, "height": 31, "left": 203}, "words": "胺后,脑脊液(CSF)中的药物浓度差异较大,并未总能达到或维持脑脊液的治疗浓度。因此"}, {"probability": {"variance": 3e-06, "average": 0.998773, "min": 0.993515}, "location": {"width": 532, "top": 558, "height": 32, "left": 204}, "words": "不推荐利奈唑胺经验性用于儿童患者的中枢神经系统感染"}, {"probability": {"variance": 2.6e-05, "average": 0.998132, "min": 0.976197}, "location": {"width": 814, "top": 592, "height": 32, "left": 248}, "words": "已在刚出生至17岁的儿童患者中对利奈唑胺的药代动力学进行了评价。一般而言,基于"}, {"probability": {"variance": 2e-06, "average": 0.99922, "min": 0.994196}, "location": {"width": 861, "top": 624, "height": 32, "left": 203}, "words": "体重的利奈唑胺清除率会随着儿童患者年龄的增长而逐渐降低。然而,对于出生后不到7天"}, {"probability": {"variance": 0.000264, "average": 0.995411, "min": 0.894669}, "location": {"width": 862, "top": 656, "height": 33, "left": 201}, "words": "的早产儿(<34孕周),其利奈唑胺清除率通常比出生7天以内的足月儿低。因此,出生7天"}, {"probability": {"variance": 0.000875, "average": 0.994141, "min": 0.802986}, "location": {"width": 859, "top": 689, "height": 33, "left": 200}, "words": "以内的早产儿需采用替代利奈唑胺剂量方案,即10mg/kg每12小时给药一次(见【药代动"}, {"probability": {"variance": 0.00014, "average": 0.996068, "min": 0.947729}, "location": {"width": 382, "top": 723, "height": 27, "left": 202}, "words": "力学】一特殊人群、儿童和【用法用量】"}, {"probability": {"variance": 2e-06, "average": 0.999092, "min": 0.993021}, "location": {"width": 818, "top": 756, "height": 30, "left": 244}, "words": "在有限的临床经验中,6例儿童患者中的5例(83%),利奈唑胺对其所感染的革兰阳性"}, {"probability": {"variance": 0.002248, "average": 0.99013, "min": 0.682765}, "location": {"width": 852, "top": 788, "height": 32, "left": 198}, "words": "病原体的最低抑菌浓度(MIC)为4mcg/ml,经利奈唑胺治疗后临床痊愈。然而,与成人相比"}, {"probability": {"variance": 1e-05, "average": 0.998766, "min": 0.979501}, "location": {"width": 863, "top": 820, "height": 33, "left": 200}, "words": "儿童患者的利奈唑胺的清除率和全身药物暴露量(AUC)变化范围更宽。当儿童患者的临床"}, {"probability": {"variance": 4.7e-05, "average": 0.99707, "min": 0.96788}, "location": {"width": 866, "top": 852, "height": 34, "left": 197}, "words": "疗效未达到最佳时,尤其是对于利奈唑胺最低抑菌浓度为4mcg/ml的病原体,在做疗效评估"}, {"probability": {"variance": 7e-06, "average": 0.998609, "min": 0.983582}, "location": {"width": 872, "top": 885, "height": 33, "left": 194}, "words": "时应考虑其较低的全身暴露药量、感染部位及其严重程度以及其基础疾病(见【药代动力学】"}, {"probability": {"variance": 0.000327, "average": 0.992365, "min": 0.929235}, "location": {"width": 301, "top": 918, "height": 27, "left": 218}, "words": "特殊人群、儿童和【用法用量】)"}, {"probability": {"variance": 1e-06, "average": 0.998847, "min": 0.99761}, "location": {"width": 120, "top": 981, "height": 30, "left": 200}, "words": "【老年用药】"}, {"probability": {"variance": 0.010841, "average": 0.975192, "min": 0.44057}, "location": {"width": 809, "top": 1016, "height": 27, "left": 253}, "words": "在11期对照研究中,2046例患者接受了利奈唑胺治疗,其中589(29%)例为65岁或"}, {"probability": {"variance": 0.000279, "average": 0.99493, "min": 0.893992}, "location": {"width": 868, "top": 1048, "height": 29, "left": 194}, "words": "65岁以上的患者;253例(12%)患者年龄大于等于75岁。未见利奈唑胺在这些患者与年轻"}, {"probability": {"variance": 1e-06, "average": 0.999115, "min": 0.995364}, "location": {"width": 328, "top": 1080, "height": 28, "left": 190}, "words": "患者之间有安全性和有效性的差异"}, {"probability": {"variance": 2.9e-05, "average": 0.996168, "min": 0.986175}, "location": {"width": 162, "top": 1143, "height": 27, "left": 198}, "words": "【药物相互作用】"}, {"probability": {"variance": 4e-06, "average": 0.998428, "min": 0.993478}, "location": {"width": 320, "top": 1177, "height": 31, "left": 192}, "words": "通过细胞色素酶P450代谢的药物"}, {"probability": {"variance": 1.6e-05, "average": 0.997585, "min": 0.975682}, "location": {"width": 828, "top": 1210, "height": 31, "left": 233}, "words": "在大鼠中,利奈唑胺不是细胞色素酶P450(CYP450)的诱导剂。另外,利奈唑胺不抑制"}, {"probability": {"variance": 0.000399, "average": 0.991812, "min": 0.896925}, "location": {"width": 850, "top": 1242, "height": 33, "left": 188}, "words": "有临床意义的人类细胞色素同工酶(如1A2、2C9、2C19、2D6、2E1和3A4)的活性。所以"}, {"probability": {"variance": 0.003358, "average": 0.989724, "min": 0.627964}, "location": {"width": 866, "top": 1275, "height": 30, "left": 196}, "words": "预计利奈唑胺不会影响经这些主要细胞色素同工酶代谢的药物的药代动力学。与利奈唑胺联"}, {"probability": {"variance": 0.003234, "average": 0.988539, "min": 0.617994}, "location": {"width": 873, "top": 1308, "height": 31, "left": 187}, "words": "合用药,不会显著改变主要由CYP2C9进行代谢的(S)-华法林的药代动力学性质。华法林、苯"}, {"probability": {"variance": 1.5e-05, "average": 0.997739, "min": 0.98108}, "location": {"width": 719, "top": 1340, "height": 30, "left": 184}, "words": "妥因等药物,作为CYP2C9的底物,可与利奈唑胺合用而无须改变给药方案"}, {"probability": {"variance": 6e-06, "average": 0.997577, "min": 0.994039}, "location": {"width": 74, "top": 1375, "height": 25, "left": 182}, "words": "抗生素"}, {"probability": {"variance": 2.7e-05, "average": 0.997461, "min": 0.974488}, "location": {"width": 716, "top": 1408, "height": 28, "left": 228}, "words": "氨曲南:当二者合用时,利奈唑胺与氨曲南的药代动力学特性均未发生改变"}, {"probability": {"variance": 8e-06, "average": 0.998535, "min": 0.986228}, "location": {"width": 762, "top": 1441, "height": 29, "left": 226}, "words": "庆大霉素:当二者合用时,利奈唑胺与庆大霉素的药代动力学特性均未发生改变"}, {"probability": {"variance": 2e-05, "average": 0.996945, "min": 0.98913}, "location": {"width": 94, "top": 1473, "height": 27, "left": 182}, "words": "抗氧化剂"}, {"probability": {"variance": 2e-06, "average": 0.99916, "min": 0.994163}, "location": {"width": 832, "top": 1508, "height": 27, "left": 225}, "words": "对健康志愿者进行了利奈唑胺与抗氧化剂维生素C和维生素E的潜在药物相互作用的研"}, {"probability": {"variance": 0.000851, "average": 0.991755, "min": 0.813218}, "location": {"width": 876, "top": 1540, "height": 28, "left": 180}, "words": "究。受试者在第1天口服600mg利奈唑胺,并在第8天再次服用600mga第2-9天,给予受"}, {"probability": {"variance": 0.007521, "average": 0.972597, "min": 0.500497}, "location": {"width": 827, "top": 1572, "height": 30, "left": 178}, "words": "试者维生素C(1000mg/天)或维生素E(800IU/天)。与维生素C合用时,利奈唑胺的A"}, {"probability": {"variance": 2e-06, "average": 0.998662, "min": 0.994535}, "location": {"width": 147, "top": 1632, "height": 23, "left": 543}, "words": "第17页,共29页"}, {"probability": {"variance": 0.013362, "average": 0.921491, "min": 0.683832}, "location": {"width": 114, "top": 1659, "height": 20, "left": 559}, "words": "辉瑞——机密"}], "language": 3}